Journal of Research in Pharmacy Practice
Volume:11 Issue: 4, Oct-Dec 2022

Medical representatives (MRs) frequently interact with physicians who may have different perceptions about and expectations from product promotional activities by pharmaceutical companies, especially through MRs. This can affect their prescribing practice. We explored the views and perceptions of MRs and physicians about the role of MRs and pharmaceutical advertisements in Saudi Arabia.

Semi-structured interviews were conducted virtually through the ZOOM application with five MRs and five physicians from July to October 2022. The participants were recruited from the Makkah region in Saudi Arabia on a convenience sampling basis and through the snowballing method. The interviews were recorded with the consent of the participants, transcribed verbatim, and thematically analyzed.

Data saturation was found to be achieved with four interviews from each group of participants. Thematic analysis generated 338 codes which were categorized into 31 subthemes. These subthemes were further categorized into 11 overarching themes: “MR daily work,” “Role of MRs in healthcare and their future,” “Value of MRs in healthcare,” “Pros and cons of the MR career,” “MRs in the COVID‑19 pandemic,” “Differences between the pharmaceutical companies,” “Goods and not-so-goods about the MRs,” “Suggestions provided by physicians for MRs and pharmaceutical companies,” “Marketing strategies of different pharmaceutical companies,” “Experience of MRs” and “Support provided by pharmaceutical companies.”

Our pilot study sheds light on the role of MRs and pharmaceutical advertisement from MRs’ and physicians perspectives. Several recommendations can be drawn from our findings to make the interactions between MRs and physicians more effective and improve pharmaceutical advertisement, prescribing practices, and patient care.

The current study aims to investigate high- versus low-dose dexamethasone administration to control the disease with minor complications.

The current multicentric randomized clinical trial was conducted on 119 patients with COVID-19 pneumonia and assigned into two groups of low-dose (8 mg daily intravenous dose for at least 7 days or until discharge) (n = 61) versus high-dose dexamethasone (24 mg for 3 days followed by daily 8 mg for the at least 4 days later or until discharge) (n = 58) during 2020–2021. Oxygen saturation, dyspnea severity based on the Borg scale, and laboratory indices were assessed at 3, 5, and 7 days of corticosteroid therapy. Patients were compared regarding the length of hospitalization, intensive care unit (ICU) admission requirement, and noninvasive or invasive ventilation. The other investigations included corticosteroid‑related adverse effects and mortality rates within a month after the medications.

Oxygen saturation, Borg scale, and C‑reactive protein levels were significantly altered by the time in both the groups (P < 0.05). In contrast, the trend of improvements in Borg scale (P = 0.007) and lactate dehydrogenase levels (P = 0.034) were superior in high-dose treated cases. Drug-related adverse (P = 0.809), mortality rate (P = 0.612), hospitalization duration (P = 0.312), ICU admission requirement (P = 0.483), and noninvasive (P = 0.396) and invasive ventilation (P = 0.420) did not differ between the groups.

According to this study, low- versus high-dose dexamethasone therapy did not affect the outcomes, so low‑dose dexamethasone is recommended for COVID-19 pneumonia to achieve optimal results and prevent potential adverse events.

This study aimed to assess the efficacy and safety of topical timolol in treating facial angiofibromas (FAs) in pediatric patients with tuberous sclerosis complex (TSC).

A prospective clinical trial was conducted involving 15 children diagnosed with TSC and presenting with FAs. The participants were administered topical timolol gel 0.5% twice daily. Prior to the intervention, the severity of FAs in each patient was evaluated using the FA severity index (FASI), which assessed erythema, size, and extent of lesions. Clinical response was assessed at weeks 2 and 4 during the intervention period as well as 1 month after discontinuation of treatment.

Four weeks after discontinuing topical timolol 0.5%, statistically significant reductions were observed in the mean FASI score, erythema, size, and extent of lesions (P < 0.0001, P < 0.0001, P = 0.012, P = 0.008, respectively). FASI scores at 4 and 12 weeks postintervention, as well as 4 weeks after treatment cessation, demonstrated a significant decrease compared to baseline (P < 0.001). Erythema and extension scores also exhibited a significant decrease 1 month after treatment cessation compared to baseline (P < 0.05), while the mean size of lesions before and after the intervention did not show a statistically significant difference (P = 0.004).

Topical timolol 0.5% represents a cost‑effective and readily available treatment option for pediatric patients with FAs associated with tuberous sclerosis.

The use of over-the-counter (OTC) drugs and complementary and alternative medicines (CAM) as initial options by parents is common in the pediatric population. Despite the widespread use of parent-directed medication (PDM) among the pediatric population, we have scarce data in the Indian context. This study was done to assess the PDM practices and its determinants in the Indian population.

It was a descriptive cross-sectional study assessing a representative sample of 284 parents of pediatric patients visiting the pediatrics department of a tertiary care hospital.

Majority (64.08%; 182 out of 284) of the parents agreed to have used some form of PDM in the past 3 months. While higher socioeconomic status and having 2 or more children were associated with higher practice of PDM (P < 0.05), it was similar between educated or uneducated parents, rural or urban backgrounds, and nuclear or joint families (P > 0.05). CAM was the most commonly used option (58.12%; 161 out of 277), followed by OTC conventional allopathic medications (41.88%; 116 out of 277). Homeopathic medicines were the most preferred alternative therapy under the Alternative Medical System Category of National Centre for Complementary and Alternative Medicine. Majority of parents (71.43%; 130 out of 182) were confident that the treatment chosen could not harm the health of their children and they attributed time constraints or availability of prior prescriptions as reasons for such practice.

PDM is a widespread phenomenon in the Indian pediatric population. The parents as well as the prescribers need to take a more balanced, practical, and judicious approach toward medications given to a child.

Azithromycin-induced severe cutaneous reactions occur rare. We report a case of azithromycin‑induced generalized nonbullous form of fixed‑drug eruption (FDE). A 19-year-old male consulted the dermatology department for multiple painful oval‑shaped, sharply defined, and hyperpigmented patches on his chest, abdomen, and upper limbs after consuming oral azithromycin tablets for his sore throat. The generalized nonbullous form of FDE was diagnosed, and the offending drug was stopped immediately. He was treated with antihistamines and steroids, and recovered on follow-up. This FDE is reported due to the spareseness of documentation from South India and to improve the awareness among the prescribing physicians about this severe cutaneous reaction (FDE) for a commonly used drug. This case report gives insight to the clinicians and health‑care workers on rare side effects caused by the commonly used antimicrobial agent, azithromycin.